

Takeda's U.S. Pricing Methodology



	CY 2019 ^{1,2}	CY 2020 ^{1,2}	CY 2021 ^{1,2}	CY 2022 ^{1,2}	CY 2023 ^{1,2}
Average list price change ³ across portfolio	2.4%	3.4%	4.1%	4.5%	4.4%
Average net price change ⁴ across portfolio	(1.6%)	1.9%	1.0%	2.7%	3.5%
Average discount ⁵ across portfolio	40%	42%	42%	43%	44%

- 1) All information in this table refers to branded oral and infusion products marketed in the U.S. by Takeda's U.S. Business Unit and Oncology Business Unit during the listed calendar years. Percentage changes are shown for each calendar year against the prior calendar year. Our calculation methodology was revised beginning CY 2019 due to changes in our portfolio following the Shire acquisition. This information is not audited and the methodologies used may differ from other companies.
- 2) Annual percent change vs. prior calendar year was calculated at a product level and weighted across Takeda's U.S. Product Portfolio based on product sales.
- 3) Average List Price Change represents the year-over-year change in the wholesale acquisition cost (WAC), as a weighted average across all products in the U.S. product portfolio.
- 4) Average Net Price Change represents the year-over-year change in average net price, which is WAC less rebates, discounts, and channel fees.
- 5) The amount of rebates, discounts, and channel fees represents an estimate by the company based upon our analysis of currently available internal data.